QNRX
ACHAT TOTAL: 28685 titres (~174979 USD)
- Insiders
- Carter Denise P., Culverwell Anthony James, Lawlor Sally Bridget, Myers Michael
- Total bought
- $174,978
- Total sold
- —
- Last activity
- 2026-08-31
- Last synced
-
2026-09-03 10:10:39
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Neutral signal Scored 2026-09-03
QNRX presents a compelling event-driven setup: a strong insider cluster buy (score 85, confidence 0.8) immediately following statistically significant Phase 2/3 interim data for QRX003 and a $50M financing round signals…
The first sentence of the analysis written for QNRX on 2026-09-03 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebitda Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Net Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Current Ratio | 3.607 | 3.570 | 3.151 | 3.790 | 1.792 | |
| Quick Ratio | 3.607 | 3.570 | 3.151 | 3.790 | 1.792 | |
| Solvency Ratio | -2.160 | -1.362 | -1.319 | -1.316 | -2.455 | |
| Cash Ratio | 688.326 | 0.867 | 0.670 | 0.811 | 1.635 | |
| Price To Earnings Ratio | -1.357 | -0.010 | -0.015 | -52.224 | -3.837 | |
| Price To Earnings Growth Ratio | 0.014 | 0.000 | -0.000 | 0.525 | -0.041 | |
| Forward Price To Earnings Growth Ratio | 0.014 | 0.000 | -0.000 | 0.525 | -0.041 | |
| Price To Earnings Diluted Ratio | -1.357 | -0.010 | -0.015 | -52.224 | -3.837 | |
| Price To Earnings Diluted Growth Ratio | 0.014 | 0.000 | -0.000 | 0.525 | -0.041 | |
| Price To Book Ratio | 1.648 | 0.009 | 0.022 | 66.326 | 125.416 | |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Price To Free Cash Flow Ratio | -1.597 | -0.011 | -0.016 | -56.268 | -12.987 | |
| Price To Operating Cash Flow Ratio | -1.597 | -0.011 | -0.016 | -57.926 | -14.406 | |
| Debt To Assets Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Debt To Equity Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.554 | 1.707 | 2.149 | 1.952 | 14.241 | |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Ratio | -2.441 | -1.879 | -2.196 | -2.404 | -1.250 | |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | 1.000 | 1.000 | 1.029 | 1.109 | |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 | -11.992 | -18.588 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | -12.965 | -5.560 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Capital Expenditure Coverage Ratio | -3,385,248.500 | 0.000 | -2,088,357.062 | -33.923 | -9.152 | |
| Dividend Paid And Capex Coverage Ratio | -3,385,248.500 | 0.000 | -2,088,357.062 | -0.129 | -9.152 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | -6.957 | 0.000 | |
| Enterprise Value Multiple | 241.742 | 0.399 | 0.265 | -57.033 | -3.696 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% |
| Ebit Margin | 0.0% | 0.0% | 0.0% |
| Ebitda Margin | 0.0% | 0.0% | 0.0% |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% |
| Net Profit Margin | 0.0% | 0.0% | 0.0% |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% |
| Current Ratio | 3.607 | ▲0.037 | ▲0.425 |
| Quick Ratio | 3.607 | ▲0.037 | ▲0.425 |
| Solvency Ratio | -2.160 | ▼-0.797 | ▼-0.438 |
| Cash Ratio | 688.326 | ▲687.459 | ▲549.864 |
| Price To Earnings Ratio | -1.357 | ▼-1.348 | ▲10.131 |
| Price To Earnings Growth Ratio | 0.014 | ▲0.013 | ▼-0.086 |
| Forward Price To Earnings Growth Ratio | 0.014 | ▲0.013 | ▼-0.086 |
| Price To Earnings Diluted Ratio | -1.357 | ▼-1.348 | ▲10.131 |
| Price To Earnings Diluted Growth Ratio | 0.014 | ▲0.013 | ▼-0.086 |
| Price To Book Ratio | 1.648 | ▲1.639 | ▼-37.036 |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 |
| Price To Free Cash Flow Ratio | -1.597 | ▼-1.586 | ▲12.579 |
| Price To Operating Cash Flow Ratio | -1.597 | ▼-1.586 | ▲13.194 |
| Debt To Assets Ratio | 0.000 | 0.000 | 0.000 |
| Debt To Equity Ratio | 0.000 | 0.000 | 0.000 |
| Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Financial Leverage Ratio | 1.554 | ▼-0.152 | ▼-2.766 |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Ratio | -2.441 | ▼-0.562 | ▼-0.407 |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | 0.000 | ▼-0.028 |
| Debt Service Coverage Ratio | 0.000 | 0.000 | ▲6.116 |
| Interest Coverage Ratio | 0.000 | 0.000 | ▲3.705 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Capital Expenditure Coverage Ratio | -3385248.500 | ▼-3385248.500 | ▼-2290518.773 |
| Dividend Paid And Capex Coverage Ratio | -3385248.500 | ▼-3385248.500 | ▼-2290525.531 |
| Dividend Payout Ratio | 0.000 | 0.000 | ▲1.391 |
| Enterprise Value Multiple | 241.742 | ▲241.343 | ▲205.407 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $21.6M | $87K | $126K | $491.3M | $82.4M | |
| Enterprise value | -$3.80B | -$3.5M | -$2.3M | $488.4M | $74.9M | |
| EV / Sales | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | |
| EV / Op. cash flow | 280.37x | 0.45x | 0.29x | -57.59x | -13.10x | |
| EV / Free cash flow | 280.37x | 0.45x | 0.29x | -55.94x | -11.81x | |
| EV / EBITDA | 241.74x | 0.40x | 0.27x | -57.03x | -3.70x | |
| Net debt / EBITDA | 243.12x | 0.41x | 0.28x | 0.33x | 0.37x | |
| Current ratio | 3.61x | 3.57x | 3.15x | 3.79x | 1.79x | |
| Income quality | 0.85x | 0.87x | 0.91x | 0.90x | 0.27x | |
| Graham net-net | $3K | $2K | $6K | $7 | -$141 | |
| Tax burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 100.0% | 100.0% | 100.0% | 108.2% | 105.4% | |
| Working capital | $14.5M | $10.7M | $7.7M | $9.8M | $3.6M | |
| Invested capital | $397.8M | $11.2M | $8.3M | $10.5M | $4.4M | |
| Return on assets | -77.5% | -57.1% | -71.4% | -64.9% | -229.4% | |
| Operating ROA | -90.3% | -68.4% | -70.4% | -77.7% | -113.0% | |
| Return on tangible assets | 4.4% | -58.9% | -75.0% | -68.2% | -251.1% | |
| Return on equity | -120.5% | -97.4% | -153.4% | -126.7% | -3266.6% | |
| Return on invested capital | -109.7% | -82.7% | -109.2% | -84.7% | -126.8% | |
| Return on capital employed | -109.7% | -82.7% | -109.2% | -84.7% | -126.8% | |
| Earnings yield | -73.1% | -10280.5% | -6880.2% | -1.9% | -26.0% | |
| Free cash flow yield | -62.6% | -9012.8% | -6229.0% | -1.8% | -7.7% | |
| Capex / Op. cash flow | -0.0% | 0.0% | -0.0% | -2.9% | -10.9% | |
| Capex / Depreciation | 0.0% | 0.0% | 0.0% | 240.3% | 600.7% | |
| Capex / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| SG&A / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Intangibles / Total assets | 1880.0% | 3.1% | 4.8% | 4.9% | 8.6% | |
| Days sales outstanding | 0d | 0d | 0d | 0d | 0d | |
| Days payables outstanding | 0d | 0d | 0d | 0d | 0d | |
| Operating cycle | 0d | 0d | 0d | 0d | 0d | |
| Cash conversion cycle | 0d | 0d | 0d | 0d | 0d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+24700.5%EV / Sales n/aEV / EBITDA ▲+60486.3%EV / Op. cash flow ▲+279.919Earnings yield ▲+102.074
Profitability
Return on equity ▼-0.231Return on assets ▼-0.205Return on invested capital ▼-0.271Return on capital employed ▼-0.271Operating ROA ▼-0.219Income quality ▼-0.023Tax burden 0.000
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▲+0.037Net debt / EBITDA ▲+242.710Working capital ▲+3715233.000Invested capital ▲+386565899.000Intangibles / Total assets ▲+18.769
Change over 5 years
Valuation
Market cap ▼-73.8%EV / Sales n/aEV / EBITDA ▲+6639.9%EV / Op. cash flow ▲+293.467Earnings yield ▼-0.471
Profitability
Return on equity ▲+31.461Return on assets ▲+1.519Return on invested capital ▲+0.171Return on capital employed ▲+0.171Operating ROA ▲+0.227Income quality ▲+0.584Tax burden 0.000
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▲+1.815Net debt / EBITDA ▲+242.750Working capital ▲+10838145.000Invested capital ▲+393363541.000Intangibles / Total assets ▲+18.713
Employee count
Peer market caps
Congressional trades
No congressional trade data synced.
Recent news
- 2026-08-28 Quoin Pharmaceuticals Stock Surges Friday: What''s Happening? Shares of Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) are rallying Friday morning following back-to-back pre-market updates detailing positive clinical trial results and a major institutional financing package.
- 2026-08-28 Quoin Pharmaceuticals Reports Positive Interim Data from Ongoing Phase 2/3 Study of QRX003 in Netherton Syndrome Interim Analysis of the First Six Patients to Complete 12 Weeks of Treatment Met Pre-Specified Alpha Adjusted Target for Primary Endpoint with Statistical Significance Four of Six (66.7%) Participants Achieved the Target 1-Grade or Greater Improvement in Investigator Global Assessment at Week 12 (p=0.0087) With Statistical Significance versus the Pre-Specified Alpha of 0.0215 Key Secondary Endpoint of Global Impression of Change Also Achieved Statistical Significance at Week 12 (p=0.0070) Versus the Pre-Specified Alpha of 0.0215 All Three Participants with Moderate-Severe Pruritus (Itch) at Baseline Achieved a Clinically Meaningful Outcome of at Least a 3-Grade Improvement After 12 Weeks of Treatment with QRX003 No Treatment Related Serious Adverse Events were Recorded ASHBURN, Va., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd.
- 2026-08-28 Quoin Pharmaceuticals Announces Private Placement Financing of Up to $50.0 Million ASHBURN, Va., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that it has entered into a securities purchase agreement with new and existing healthcare-focused institutional investors to raise up to approximately $50.0 million in gross proceeds, including initial upfront funding of approximately $30.8 million and up to an additional approximately $19.2 million upon the potential cash exercise of accompanying ordinary warrants at the election of the investors.
- 2026-08-14 Quoin Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2026 Financial Results – Receives FDA Conditional Approval of QYLEKI™ as the Proposed Brand Name for QRX003 for Netherton Syndrome – Reports Positive Clinical Update from Ongoing Pediatric Compassionate Use Program in Netherton Syndrome – Receives U.S. Notice of Allowance for a Patent Covering a Combination Treatment for Netherton Syndrome – Submits First-Ever IND for Peeling Skin Syndrome; FDA Clearance Received Subsequent to Quarter End, Enabling First Company-Sponsored Phase 2/3 Study to Initiate in 2H 2026 – Advances QRX009 Topical Rapamycin Platform Toward Clinical Testing in a Number of Indications ASHBURN, Va., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd.
- 2026-08-07 Quoin Pharmaceuticals to Announce Corporate Update and Second Quarter 2026 Financial Results on Friday, August 14, 2026 ASHBURN, Va., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that it plans to provide a corporate update and release its financial results for the second quarter ended June 30, 2026, before the market opens on Friday, August 14, 2026.
- 2026-07-09 Quoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin Syndrome Quoin Pharmaceuticals (NASDAQ: QNRX) receives FDA IND clearance for a Phase 2 study of QRX003 in Peeling Skin Syndrome, with initiation expected in 2H 2026
- 2026-06-30 Quoin Pharmaceuticals Receives U.S. Notice of Allowance for Patent Covering Combination Treatment for Netherton Syndrome ASHBURN, Va., June 30, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd.
- 2026-06-23 Quoin Pharmaceuticals Receives FDA Conditional Approval of QYLEKI™ as the Proposed Brand Name for QRX003 for Netherton Syndrome QRX003 Holds Orphan Drug Designation in the United States, the European Union, and Japan, Plus Fast Track and Rare Pediatric Disease Designations from the FDA Pivotal Phase 3 Study Expected to Initiate in the Second Half of 2026, with Potential NDA Filing in 2027 Positive Clinical Update from Ongoing Pediatric Compassionate Use Program Released on June 16 QRX003 Remains on Track to Potentially Become the First Approved Treatment for Netherton Syndrome ASHBURN, Va., June 23, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd.
- 2026-06-18 Quoin Pharmaceuticals Completes Establishment of Japanese Subsidiary to Advance Commercial Readiness for QRX003 Supports Quoin''s planned direct commercialization of QRX003 in Japan, one of its three core commercial territories Follows recent grant of Orphan Drug Designation to QRX003 by Japan''s MHLW ASHBURN, Va., June 18, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd.
- 2026-06-16 Quoin Pharmaceuticals Announces Positive Clinical Update from Ongoing Pediatric Netherton Syndrome Compassionate Use Program Four of Six Patients Participating in the Compassionate Use Program Were Classified as ‘Improved'' or ‘Significantly Improved'' from Baseline Assessment Across Key Clinical Endpoints All Six Patients Are Younger than 10 Years of Age, with the Youngest Being Just 6 Months Old Duration of Treatment To-Date Ranges from 3 Weeks to 15 Months No Treatment Related Adverse Events Reported for All Six Patients Additional Pediatric Patients Enrolling in Program in June and September Quoin Plans a Comprehensive Data Release, including from Ongoing Phase 2 Studies, in the Coming Months ASHBURN, Va., June 16, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd.